WO2015056710A1 - Transdermal immune preparation - Google Patents

Abstract

　Provided is a transdermal immune preparation useful in transdermal immunization. The transdermal immune preparation (1) of the present invention is characterized in being provided with a base (2) and an antigen (3) layered on the surface of the base (2), the transdermal immune preparation (1) adjusting the immune response by application to intact skin. A typical antigen is an allergen. The base (2) is a hydrophilic gel having adhesive properties. In particular, the hydrophilic gel constituting the base (2) is configured from hyaluronic acid, glycerin, Cosmol 13, and HiPAS10, the weight ratio of these components in the stated order optimally being 0.02:3:4.5:10.

Description

Transdermal immunotherapy

The present invention relates to a transdermal immunization preparation useful for transcutaneous immunization for regulating immune response.

In the treatment of food allergies, immunotherapy by allergen administration is performed with the goal of complete cure. The administration route is mainly subcutaneous injection, sublingual or oral, but it has not been established as a therapeutic method from the viewpoint of effectiveness and safety. For example, in the case of oral immunotherapy, there are problems with its safety, and both rapid and slow methods have induced symptoms during or during the allergen load increase, and the incidence of adverse events is high, prompting patients to be prepared and determined By the way, it can be said that it is a treatment method that exceeds the safety standards required for medical treatment at present. In terms of effectiveness, there are many cases in which the allergen load cannot be increased to the target value, and the patient repeats provoking symptoms during that time. Since it is necessary to reduce the load not only during the increase period but also during the maintenance period, it is currently impossible to overcome by improving the increase method.

On the other hand, transcutaneous immunotherapy using the immune system of the skin is not yet a general treatment for allergic diseases, but systemic symptoms are compared to conventional subcutaneous injection, sublingual and oral immunotherapy. Since the risk of induction is low, it is expected as a relatively safe and simple method.

In order to establish transcutaneous immunity, both the passage of the antigen through the skin and the immune response to the antigen are required. Antigens are polymeric substances that are usually larger than 1000 daltons and are extremely difficult to pass through the skin. Therefore, in order to perform transcutaneous immunization, the stratum corneum is peeled from the skin, and a preparation containing an antigen is applied to the skin from which the stratum corneum has been peeled (Patent Document 1). However, exfoliation of the stratum corneum from the skin has not only troublesome antigen administration, but also has the disadvantage that there is a risk of bacterial infection from the exfoliation site.

Therefore, research on transdermal immunization preparations that can be applied to intact skin without peeling off the stratum corneum from the skin to establish transcutaneous immunity has been actively conducted. For example, “one or more antigens and adjuvant components” A formulation for transcutaneous immunization comprising: wherein at least one of the components is dry, whereby application of the formulation to intact skin induces an antigen-specific immune response and Manufacturing a dry formulation for transcutaneous immunization, comprising: (a) providing at least one immunoactive component, wherein the formulation comprises at least one immunoactive component having antigenic activity; b) dissolving at least one of the immunoactive ingredients to create an immunoactive liquid; (c) drying the immunoactive liquid on a solid substrate such as a bandage; and (d) combining the immunoactive ingredients together Manufacturing process The above-mentioned manufacture "(Patent Document 2) is proposed, including in any order, wherein at least one of the immunologically active ingredients is dry, at least until the formulation is applied to the skin of the subject to be immunized. ing.

 € ¢ Although transdermal immunization products applied to free skin have already been published, there is room for improvement in their contents (Patent Document 3)

Japanese Patent Laid-Open No. 10-316585 Special Table 2003-523937 WO2008-105504 A1

[The skin covering our bodies is always exposed to the danger of pathogen invasion from the outside world. On the other hand, the living body forms a first-line defense mechanism by providing a physical barrier called a stratum corneum and an immune barrier centering on Langerhans cells existing in the epidermis layer. Therefore, if a sufficient amount of antigen protein can be delivered to the epidermis layer through the stratum corneum, the antigen protein is captured by Langerhans cells, the control tower of the immune system, and an antigen-specific immune response can be efficiently induced. Conceivable. However, the permeability of the stratum corneum to biopolymers such as proteins is extremely poor, and the antigenic protein cannot be delivered to the epidermis layer simply by applying a solution preparation to the skin.

The problem to be solved by the present invention is to provide a patch preparation that permeates the stratum corneum and sends the antigen protein to the epidermis layer, that is, a transdermal immunization preparation, by a simple technique.

The transdermal immunization preparation of the present invention comprises a base composed of an adhesive hydrophilic gel and an antigen laminated on the surface of the base, and regulates the immune response by application to intact skin. Features.
In the present invention, “modulate” means both positive regulation, that is, regulatory induction that activates and promotes the immune system, and negative regulation, that is, regulation that suppresses the immune system.

The present invention intends to adapt the hydrophilic gel patch that we have developed so far as a device for an effective transdermal vaccine preparation for preventing infection, that is, a “paste vaccine preparation”, to transdermal immunotherapy for allergic diseases. It is.

Transdermal immunizations are thought to deliver antigens to cells of the immune system and induce immune responses without the aid of adjuvants. The antigen passes through the normal protective outer layer of the skin (eg, the stratum corneum) and presents antigen-presenting cells (eg, macrophages, dendritic cells, skin dendritic cells, directly or directly to T lymphocytes, The immune response is induced through B lymphocytes or Kupffer cells). Optionally, the antigen may pass through the stratum corneum via hair follicles or skin organelles (eg, sweat glands, sebaceous glands).

Here, an antigen means a substance that induces a specific immune response when presented to immune cells of an organism. An antigen may comprise a single immunogenic epitope or multiple immunogenic epitopes recognized by a B cell receptor (ie, an antibody on the membrane of a B cell) or a T cell receptor.

As the antigen, a pathogen-derived antigen capable of infecting an organism selected from the group consisting of bacteria, viruses, fungi, and parasites, a pathogen-derived that can infect cells (for example, tumor cells or normal cells) Antigens.
Examples of the antigen include a tumor-related antigen or a self antigen. Furthermore, examples of the antigen include allergens such as pollen, animal dander, mold, dust mite, flea antigen, salivary allergen, grass, food (for example, peanuts and other nuts), and Betv1. Thus, the antigen may be a food allergen such as a milk allergen or an egg allergen.

Chemically, the antigen may be a carbohydrate, glycolipid, glycoprotein, lipid, lipoprotein, phospholipid, polypeptide or a chemical or recombinant conjugate thereof. Antigens are obtained by recombinant means, chemical synthesis or purification from natural sources, preferably proteinaceous antigens or conjugates with polysaccharides. The antigen may be at least partially purified cell-free. Alternatively, the antigen may be provided in the form of a live virus, an attenuated live virus, or an inactivated virus. The antigen may be a nucleic acid (eg, DNA, RNA, cDNA, cRNA) encoding the antigen as appropriate.

When the molecular weight of the antigen is 1,000 daltons or less, it tends to be absorbed inside when dropped in a solution state on a base made of a hydrophilic polymer substance, and the antigen may not be sufficiently concentrated on the surface of the base. As such, the molecular weight of the antigen is preferably greater than 1000 daltons.

The base is composed of an adhesive hydrophilic gel composed of a hydrophilic polymer substance that swells by absorbing water and / or water-containing alcohol. Since the antigen is dissolved or suspended in water and / or hydrous alcohol, dropping the aqueous solution or suspension onto a base composed of a hydrophilic polymer substance that absorbs and swells water and / or hydrous alcohol increases the hydrophilicity. Since the molecular substance absorbs water and / or hydrous alcohol, a concentrated antigen layer is laminated on the base surface.

Examples of the hydrophilic polymer substance include polyalkyl alkoxy acrylate polymer substances, starch-acrylic acid graft polymer substances, polyacrylate polymer substances, polyvinyl alcohol polymer substances, and vinyl acetate- Examples thereof include acrylate polymer materials, polyvinyl pyrrolidone polymer materials, isobutylene-maleic acid polymer materials, N-vinylacetamide polymer materials, and the like.

When the hydrophilic polymer substance is cross-linked, it is preferable that the polymer substance has no or no decrease in strength even if it swells due to absorption of water and / or water-containing alcohol. As the crosslinking method, any conventionally known method may be employed. For example, a metal complex such as a known polyfunctional isocyanate or aluminum acetylacetonate may be added as a crosslinking agent to the hydrophilic polymer substance.

The base is a hydrophilic polymer substance, 100 parts by weight of a copolymer comprising 40 to 60% by weight of methoxyethyl acrylate, 30 to 40% by weight of lauryl (meth) acrylate, and 10 to 25% by weight of a polar monomer. More preferably, it is composed of 30 to 50 parts by weight of octyldodecyl lactate, 20 to 50 parts by weight of glycerin, and 0.1 to 0.5 part of hyaluronic acid.

Examples of the polar monomer include N-vinyl-2-pyrrolidone, (meth) acrylic acid, 2-hydroxyethyl acrylate and the like. When the content of methoxyethyl acrylate in the copolymer is increased, gelation is likely to occur during the polymerization and insolubility tends to occur, and the tackiness of the obtained pressure-sensitive adhesive tends to decrease. Moreover, when content of lauryl (meth) acrylate decreases, the adhesiveness of the obtained adhesive tends to decrease. Further, when the content of the polar monomer is decreased, the cohesive force of the obtained adhesive tends to be reduced, and when the content is increased, the adhesive suitable for sticking to the skin tends not to be obtained. The ratio of methoxyethyl, lauryl (meth) acrylate and polar monomer is preferably within the above range. Lactic acid octyldodecyl, glycerin and hyaluronic acid have the effect of further improving the hydrophilicity of the hydrophilic polymer substance and increasing the water absorbability and improving the adhesiveness to the skin and improving the skin adhesiveness, If the amount is small, the effect may be small. If the amount is large, the hydrophilic polymer substance becomes too soft and the practicality may be lowered, so the above range is preferable.

The hydrophilic gel may be composed of hyaluronic acid, glycerin, cosmol 13 and an acrylic pressure-sensitive adhesive. Their weight ratio is preferably 0.02: 3: 4.5: 10 in this order. As the acrylic adhesive, HiPAS10 (trade name) manufactured by Kosmedy Pharmaceutical Co., Ltd. can be used.

The transdermal immunity preparation of the present invention has an antigen layer laminated on the surface of the base, but the thickness of the base is not particularly limited, but if it is too thin, the antigen water and / or aqueous alcohol solution or suspension water And / or may not be able to absorb water-containing alcohol sufficiently, and if it is too thick, flexibility may be lost and contact with the skin may be reduced, so 20 to 5000 μm is preferable, and 50 to 2000 μm is more preferable. . The shape of the base is not particularly limited, but is preferably a patch. A support film such as a release sheet, a polyethylene film, a polypropylene film, a polyethylene terephthalate film, or a urethane film may be laminated on the surface of the base and the antigen layer.

The base preferably contains a plasticizer that is compatible with the hydrophilic polymer substance in order to improve the absorbability of water and / or hydrous alcohol. The plasticizer may be hydrophilic and is preferably a liquid plasticizer. Examples thereof include glycerin, ethylene glycol, polyethylene glycol, dodecyl octyl lactate, sorbitan monooleate, sorbitan monopalmitate, and polyoxyethylene sorbitan monooleate.

In addition, the base preferably contains a chemical absorption enhancer in order to promote percutaneous absorption of the antigen. As the chemical absorption enhancer, any conventionally known chemical absorption enhancer can be used. For example, alcohols such as menthol, camphor, and cetyl alcohol; fatty acid esters such as isopropyl palmitate and isopropyl myristate; monolaurin Examples thereof include glycerin esters such as glycerin acid and glyceryl monooleate; acid amides such as lauric acid diethanolamide; neutral surfactants such as polyethylene glycol dilauryl ether. If the amount of the chemical transdermal absorption enhancer is too small, the percutaneous absorption effect will not be improved, and if it is too large, the adhesiveness of the base will be lowered. Is preferred.

Furthermore, by including an enzyme such as protease, esterase, lipase or the like in the base, these enzymes act on the skin stratum corneum and can further promote percutaneous permeation of the antigen. Examples of the protease include pepsin, trypsin, chymotrypsin, papain, collagenase, elastase, endoproteinase, pronase and the like, and examples thereof include pepsin, trypsin, chymotrypsin, papain and collagenase. Lipase can be extracted and purified from animal pancreas, but a commercially available product may be used.

The transdermal immunization preparation of the present invention does not need to contain adjuvant, but the antigen layer or base may contain adjuvant. An adjuvant is a substance that helps induce an immune response to an antigen, and a substance may act as both an adjuvant and an antigen by inducing an immune stimulus and a specific antibody or T cell response.

A transdermal immunological preparation is prepared by dropping an aqueous solution or suspension in which an antigen is dissolved or suspended in water and / or hydrous alcohol onto the surface of the base, and absorbing the water and / or hydrous alcohol into the base. Can be manufactured. Antigen is concentrated on the base surface to form an antigen layer.

As water or water-containing alcohol for dissolving or suspending the antigen, water, alcohol containing water, alcohol such as ethanol, or a buffer solution thereof can be preferably used. Examples of the buffer include Ca ⁺⁺ / Mg ⁺⁺ phosphate-free buffered saline (PBS), normal saline (150 mM NaCl aqueous solution), Tris buffer, and the like.

The antigen is generally solubilized with 10 mM acetic acid if the antigen is not dissolved in water or hydrous alcohol and its buffer, and then diluted to a desired volume with neutral water, hydroalcohol and buffer. In addition, an antigen that dissolves only at acidic pH may be solubilized with dilute acetic acid, and then diluted with acetic acid-PBS as a diluent at acidic pH. Hydrophobic antigens that are insoluble in themselves (eg, hepatitis A virus, polypeptides containing domains across the membrane, etc.) may be suspended in a surfactant.

Next, the obtained aqueous solution or suspension is dropped on the surface of the base, and water or hydrous alcohol is absorbed into the base. Since the base is composed of a hydrophilic polymer substance that absorbs and / or swells water and / or water-containing alcohol, water and / or water-containing alcohol in an aqueous solution or suspension can easily be used as a base (hydrophilic polymer substance). Absorbed, the antigen is left behind on the surface of the base (hydrophilic polymer substance) and a concentrated antigen layer is formed.

Before applying the transdermal immunological preparation to intact skin, it is preferable to treat intact skin with an enzyme to promote percutaneous permeation of the antigen. Examples of the enzyme include enzymes such as protease, esterase and lipase described above. The enzyme treatment method is not particularly limited, and examples thereof include a method in which an enzyme aqueous solution in which an enzyme is dissolved in purified water adjusted to an appropriate pH is applied to the skin site. In that case, it is practically convenient to apply the enzyme aqueous solution soaked in filter paper or other porous simple substance.

Examples of different enzyme treatment methods include a method in which an enzyme ointment in which an enzyme is dissolved in an ointment base is applied to the skin, and a method in which an aqueous gel containing an enzyme dissolved in an aqueous gel is applied to the skin.

The current allergen immunotherapy mainly involves subcutaneous injection, sublingual administration or oral administration of allergen, but has the problems described in the problem column to be solved by the invention. Furthermore, allergen administration by injection is not only painful, but also has problems of side effects such as swelling and fever at the local site of administration. In contrast, transdermal allergen immunotherapy using hydrophilic gel patches may be superior in terms of safety and efficacy compared to conventional methods, and is said to be easy to administer and low cost. It can be a therapy that has advantages and can achieve improved patient quality of life. Further, the present invention is not limited to the treatment of food allergies, and is expected to be applicable to the development of new treatment methods for other allergic diseases as well as autoimmune diseases.

According to the present invention, a transdermal immunization preparation having a concentrated antigen layer can be easily produced, and the transdermal immunization method of the present invention can prevent and treat the balance of the immune system without causing skin irritation. It can be changed in an advantageous manner. According to the configuration of the transdermal immunization preparation of the present invention, the immunological activity is high even without an adjuvant.

FIG. 1 is a diagram of the results of transdermal allergen immunotherapy. FIG. 2 is a schematic front view of a transdermal immune preparation according to an embodiment of the present invention.

FIG. 2 is a schematic front view of a transdermally absorbable preparation according to one embodiment of the present invention. The transdermally absorbable preparation 1 includes a base 2 and an antigen 3 laminated on the surface of the base 2.
The transdermal immunization preparation of the present invention is characterized by regulating the immune response by application to intact skin. As a base, it is comprised by the hydrophilic gel which has adhesiveness.

It is possible to penetrate the stratum corneum and deliver the antigen protein to the epidermis layer by a very simple technique of immersing the antigen protein solution in a hydrophilic gel and applying this patch preparation to the mouse ear skin. It was revealed that antigen-specific antibody production can be induced (see FIG. 1).

In addition, since this antigen-specific antibody production is equivalent to the administration by injection for the production of IgE that leads to worsening of allergy (see FIG. 1), at least allergen may enter the blood and cause anaphylactic shock It is expected that it can be applied more safely than conventional subcutaneous injection methods. Furthermore, based on the basic research so far, we conducted a clinical study to evaluate the safety and efficacy in humans for hydrophilic gel patches containing tetanus and diphtheria toxoid. It has been clarified that the antibody titer against each toxoid increases. In other words, this hydrophilic gel patch can be safely applied to humans and can deliver allergens into the skin, thus enabling allergen immunotherapy superior to subcutaneous injection.・ It has the potential to become a core technology that contributes to the realization of a safe society.

The present invention uses an independently developed hydrophilic gel patch to deliver allergens transcutaneously into the living body, allowing Langerhans cells present in the epidermis layer to capture and recognize allergens, thereby improving the efficiency of antigen-specific immune responses. It is often evoked and tries to gain resistance to allergens. Langerhans cells are antigen-presenting cells that function as a control tower of the immune system, capture pathogens that have entered the living body from the skin, move to nearby lymph nodes, and transmit antigen information to immune effector cells. In order to perform percutaneous allergen immunotherapy targeting the intrinsic immunological function of the Langerhans cells, the allergen must break through the stratum corneum, which is the physical barrier of the outermost skin layer. It allows delivery to the skin tissue below the stratum corneum by keeping the local concentration of the allergen high.

Examples of the present invention are shown below, but the present invention is not limited to the examples.

[Example 1]
(Optimization of base composition)
In order to obtain an optimal base composition, five bases having the following composition and mixing weight ratio were prepared.
Base 1: Hyaluronic acid: Glycerin: Cosmol 13: HiPAS10 = 0.02: 3: 4.5: 10.
Base 2: Hyaluronic acid: Glycerin: Cosmol 13: HiPAS10 = 0.002: 0.4: 0.4: 10.
Base 3: HiPAS10 (Cosmedic Pharmaceutical's medical adhesive).
Base 4: DT2287 (National Starch Medical Adhesive).
Base 5: MASCOS 10 (Cosmed Pharmaceutical's medical adhesive).
All of these bases have appropriate tackiness.

Note that HiPAS10 (manufactured by Cosmed Pharmaceutical) is a hydrophilic acrylic adhesive, has excellent drug retention properties, can be oil-gelled, and is a suitable base for acidic and neutral drugs. HiPAS10 was prepared by using azobisisobutyronitrile as a catalyst in ethyl acetate, 43.9% by weight of methoxyethyl acrylate, 36.7% by weight of lauryl acrylate, 6.1% by weight of vinylpyrrolidone, and 3.1% by weight of acrylic acid. And 10.2% by weight of hydroxyethyl acrylate are mixed and polymerized.

A solution of the above five bases was applied to the surface of polyethylene terephthalate so that the thickness of the base layer after drying was 100 μm, and dried at 100 ° C. for 5 minutes to obtain an adhesive film. The surface was fixed on top, 100 μl of water was gently dropped, and the behavior of the dropped water after 10 minutes was observed. Base 1: Water droplet spread due to surface wetting and became 2.3 cm in diameter. Base 3 which did not spread and had a diameter of 0.7 cm: The water droplet slightly shrunk and the diameter was 0.6 cm.
Base 4 and Base 5: Water droplets shrunk and the diameter was 0.5 cm or less.

As for the base 1, HiPAS10 is a hydrophilic pressure-sensitive adhesive, and since hydrophilic substances such as glycerin and cosmol 13 are dissolved in a large amount, the affinity with water is remarkably high. When the affinity with water is high, when the antigen aqueous solution is dropped on the surface, moisture is quickly absorbed into the base and the antigen is held on the base surface. That is, the antigen is concentrated and stabilized, and when applied to the skin, the antigen can be smoothly transferred to the skin.
Therefore, it can be concluded that Base 1 is optimal.

[Example 2]
A transdermal allergen immunotherapy preparation for food allergy was developed.

(OVA immunity)
The OVA solution prepared with PBS was absorbed at 100 μg / 10 μl into the base 1 patch (1 × 2 cm ² ), and the patch surface was dried at room temperature. The thus-prepared OVA-containing patch was affixed to the mouse auricle skin three times at intervals of 2 hours for 24 hours. In addition, 100 μg of OVA was immunized intradermally into mouse auricle skin at 2-week intervals three times, and this was used as a control group.

(Collection of each sample)
Each sample was collected 2 weeks after the final immunization. Serum was obtained by centrifuging blood collected from the tail vein of mice using a hematocrit capillary tube at 5000 rpm for 15 minutes.

(Antibody titer)
OVA (10 μg / ml in 50 mM Bicarbonate buffer) was dispensed at 50 μl / well into a 96-well ELISA plate, and allowed to stand overnight at 4 ° C. for immobilization. Block ace diluted twice with PBS was added to the solidified plate at 200 μl / well for blocking (37 ° C., 2 hours). After washing once with 0.05% Tween-20 / Tris-buffered saline (TTBS), samples prepared at each concentration were added and allowed to react at room temperature for 2 hours. Thereafter, the plate was washed three times with TTBS, and HRP-conjugated goat-anti-mouse IgG (5000-fold dilution), IgG1 (5000-fold dilution), and IgG2a (2000-fold dilution) were added at 50 μl / well. After reacting at room temperature for 2 hours, it was washed 3 times with TTBS, and an HRP substrate solution was added at 100 μl / well. After 15 minutes, 2N H ₂ SO ₄ was added at 100 μl / well to stop the reaction, and the absorbance at an absorption wavelength of 450 nm and a sub wavelength of 655 nm was measured. For antibody titers, the maximum dilution ratio, which is 0.1 or more higher than that of non-immunized mice, was expressed as Reciprocal log ₂ titer. The sample and antibody were diluted with Block Ace diluted 10 times with TTBS. The production amount of the OVA-specific IgE antibody was measured using a Mouse anti-OVA IgE ELISA kit.

The measurement results are shown in FIG. The hydrophilic gel patch method of the present invention shows an effect that is not significantly different from the conventional injection method.

[Example 3]
(Stability evaluation of milk protein patch)
Test method:
A base 1 patch (1 cm × 1 cm) was prepared, 0.07 mL of a 14.3 mg / mL aqueous solution of milk protein was applied to the patch surface, and dried at room temperature to prepare a milk protein patch (milk protein content = 1 mg). /patch). The milk protein-coated surface was covered with a polyethylene terephthalate release film and sealed in an aluminum bag by heat sealing. Milk protein was quantified by storing at 4 ° C. and sampling periodically.
Quantitative method:
The milk protein patch was immersed in PBS (phosphate buffer) and shaken at 34 ° C. and 200 rpm for 1 hour to extract milk protein. Protein quantification of the extracted solution was performed by the Raleigh method.
result:
The milk protein content did not decrease during the storage period even at 6 months, confirming the stability in the patch.

[Example 4]
Transdermal immunity against egg allergy (1) IgG antibody production Test method:
A base 1 patch (1 cm × 1 cm) was prepared, and an egg protein patch (egg protein content = 1 mg / patch) was prepared by applying 0.07 mL of a 14.3 mg / mL aqueous solution of egg protein to the patch surface and drying at room temperature. Created. The obtained patch was affixed to the shaved back of a BALB / C mouse (6 weeks old, female), covered with a breathable wound dressing sheet, the patch was fixed, and applied for 24 hours for immunization. Similar immunizations were performed at 1, 2, 3 and 4 weeks.
Quantitative method:
At 3, 4, and 5 weeks, blood was collected from the mouse and serum was separated, and the IgG antibody titer of each serum was quantified by ELISA.
result:
When IgG antibody titers were measured at 3 weeks, 4 weeks and 5 weeks, the IgG antibody titers were 9 (3 weeks), 11 (4 weeks) and 14 (5 weeks). The antibody titer was high enough to be put to practical use. In addition, the unit of IgG antibody titer is Reciprocal log2 titer.

DESCRIPTION OF SYMBOLS 1 ... Percutaneous absorption preparation 2 ... Base 3 ... Antigen

Claims (7)

1. A base composed of an adhesive hydrophilic gel;
   An antigen laminated on the surface of the base,
   A transdermal immunization preparation characterized by modulating an immune response by application to intact skin.
2. The transdermal immunization preparation according to claim 1, wherein the antigen is an allergen.
3. The transdermal immunization preparation according to claim 2, wherein the allergen is a food allergen.
4. The transdermal immunization preparation according to claim 3, wherein the food allergen is a milk allergen.
5. The transdermal immunization preparation according to claim 3, wherein the food allergen is an egg allergen.
6. The hydrophilic gel comprises 100 parts by weight of a copolymer comprising 40 to 60% by weight of methoxyethyl acrylate, 30 to 40% by weight of lauryl (meth) acrylate and 10 to 25% by weight of a polar monomer, and 30 to 30% of octyldodecyl lactate. The transdermal immunization preparation according to any one of claims 1 to 5, comprising 50 parts by weight, 20 to 50 parts by weight of glycerin, and 0.1 to 0.5 parts by weight of hyaluronic acid.
7. The hydrophilic gel is composed of hyaluronic acid, glycerin, cosmol 13 and an acrylic adhesive, and the weight ratio thereof is 0.02: 3: 4.5: 10 in this order. 2. A transdermal immunological preparation according to item 1.

Images